COVID-19: Vaccines and Therapeutics
Moderna Friday submitted its request that the Food and Drug Administration authorize for emergency use its bivalent COVID-19 vaccine for children and adolescents between the ages of 12 and 17 years old. The bivalent version of its mRNA vaccine is designed to target both the original strain of SARS-…
The Centers for Disease Control and Prevention Friday updated its COVID-19 infection control guidance for U.S. health care settings based on current information. The guidance updates the circumstances when source control (respirator and face mask use) and universal personal protective equipment are…
AHA will co-host a Sept. 27 Facebook Live event with AdventHealth on the importance of getting children vaccinated and boosted against COVID-19, which will also cover the new bivalent booster shots.
Insured and uninsured Americans can receive the new bivalent Pfizer or Moderna COVID-19 booster and other COVID-19 vaccines at no cost as long as the federal government continues to purchase and distribute them, the Centers for Medicare & Medicaid Services announced today. The Centers for…
The Biden Administration will make over 170 million doses of the bivalent COVID-19 vaccine booster available to Americans for free at pharmacies, doctor’s offices, health centers, and state and local health departments, the White House announced today.
As kids head back to school, Children’s Mercy is sharing helpful information for parents and teens on COVID-19 vaccines, urging that everyone age six months and older get vaccinated. The info emphasizes the facts about COVID-19 vaccines, including how they were developed, how mRNA vaccines works…
The CDC recommended Pfizer’s updated COVID-19 vaccine booster for Americans aged 12 and older and Moderna’s updated COVID-19 vaccine booster for Americans aged 18 and older, as recommended by its vaccine advisory committee.
The Food and Drug Administration yesterday announced it has amended the emergency use authorizations for Pfizer’s and Moderna’s COVID-19 vaccines to account for new, bivalent formulations designed to install immunity against the SARS-CoV-2 omicron variant.
Pfizer applies for EUA for variant-tailored booster; unveils new efficacy data for youngest children
Pfizer yesterday announced its application for an emergency use authorization for a COVID-19 vaccine booster that is designed to protect against the SARS-CoV-2 omicron variant. The booster is meant for the 12 and older age group.
Novavax today announced the Food and Drug Administration expanded the emergency use authorization for its Adjuvanted (NVX-CoV2373) COVID-19 vaccine. Under the expanded EUA, the two-dose primary series can be administered for adolescents between the ages of 12 and 17.